Two sizable companies and a handful of small Asian issuers were listed in the US this past week. Read more here.

Amgen (AMGN) provided updates on selected product and pipeline programs, including that a Phase 1 study of AMG 513 in people living with ...

FDA aligned on single-arm Phase 3 study to support potential accelerated and full approvalOn track to dose first patient in Phase 3 trial in ...

CHATHAM, N.J. - Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP), a clinical-stage biotech company with a market capitalization of $28 million, announced today positive outcomes from its Phase 1 ...

This study will evaluate HCW9302 in patients with moderate to severe alopecia areataMIRAMAR, Fla., Feb. 03, 2025 (GLOBE ...

HCW Biologics gets US FDA nod to begin first-in-human phase 1 trial of HCW9302 to treat patients with moderate-to-severe alopecia areata: Miramar, Florida Wednesday, February 5, 2 ...

SAB BIO, (“SAB BIO”), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that is developing human ...

TransCode Therapeutics, Inc. (NASDAQ: RNAZ), the RNA oncology company committed to more effectively treating cancer using RNA therapeutics, today announced that Cohort 3 of its Phase 1 clinical trial ...

Sosei Heptares' longstanding alliance with Pfizer has advanced a first candidate into phase 2 testing ... drugs directed at G protein-coupled receptor (GPCR) targets since 2015. The GLP-1 agonist ...

Ac-SSO110 has now received FDA orphan drug designation and investigational new drug application clearance for the treatment ...

The GLP-1 receptor agonist exenatide failed to meet its primary outcome in a phase III trial of Parkinson's disease patients.

LUND, SE / ACCESS Newswire / February 6, 2025 / Alligator Bioscience (STO:ATORX) FDA feedback validates the clinical ...